Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balstilimab versus investigator's choice chemotherapy in recurrent cervical cancer after platinum-based chemotherapy
2021-002193-63Phase 3Terminated
- Sponsor
- Agenus Inc.
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of balstilimab in Cervical Cancer (CC) (2 arms), sponsored by Agenus Inc. Primary endpoint: Overall survival. Started Jul 2021; status: terminated.
02
Drugs
balstilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2021-002193-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002193-63.